Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Do patients with clinically isolated syndrome benefit from treatment with interferon β1b?

Nature Clinical Practice Neurology volume 3, pages 80–81 (2007)Cite this article

boxed-textKappos L et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242–1249

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jacobs LD et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898–904

    Article  CAS  Google Scholar 

  2. Comi G et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576–1582

    Article  CAS  Google Scholar 

  3. McDonald WI et al. (2005) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 58: 840–846

    Article  Google Scholar 

  4. Dalton CM et al. (2002) Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 52: 47–53

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. University of Vermont, College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA hillel.panitch@vtmednet.org

Authors and Affiliations

  1. H Panitch is Professor of Neurology at the University of Vermont College of Medicine and Director of the MS Center of Northern New England, Burlington, VT, USA.,

    Hillel Panitch

Authors
  1. Hillel Panitch
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panitch, H. Do patients with clinically isolated syndrome benefit from treatment with interferon β1b?. Nat Rev Neurol 3, 80–81 (2007). https://doi.org/10.1038/ncpneuro0397

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0397

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing